From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
OC rare subtype | Histological similarities | Oncogenic alterations |
---|---|---|
Low-grade serous | None | KRAS mutation (40%) |
BRAF mutation (5%) | ||
HER2 mutation (15%) | ||
Mucinous | Mucinous intestinal tumors | KRAS mutation (50%) |
BRAF mutation (5%) | ||
HER2 amplification (15%) | ||
Endometrioid | Endometrial cancer | PTEN mutation/loss (40%) |
PIK3CA mutation (20%) | ||
β-catenin mutation (40%) | ||
Clear cell | Renal cell cancer | PIK3CA mutation (35%) |
MET amplification (25%) | ||
Transitional cell/Brenners tumors of the ovary | Urothelial tumors | NA |